Results 91 to 100 of about 11,256 (207)

Exploiting Induced Vulnerability To Overcome PARPi Resistance and Clonal Heterogeneity in BRCA Mutant Triple-Negative Inflammatory Breast Cancer

, 2022
Acquired resistance and clonal heterogeneity are critical challenges in cancer treatment, and the lack of effective computational tools hampers the discovery of new treatments to overcome resistance.
Shih, David J H, Zhang, Jing, McGrail, Daniel J, Zheng, Wenjin Jim, Chen, Mei-Kuang, Hung, Mien-Chie, Yin, Jun, Yang, Liuqing, Dai, Hui, Lin, Shiaw-Yih, Wei, Rongbin, Do, Kim-Anh   +11 more
core  

FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models

The Journal of Clinical Investigation
Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) are used to treat BRCA-mutated (BRCAm) cancer patients; however, resistance has been observed. Therefore, biomarkers to indicate PARPi resistance and combination therapy to overcome that are urgently
Mei-Kuang Chen, Hirohito Yamaguchi, Yuan Gao, Weiya Xia, Jeffrey T. Chang, Yu-Chun Hsiao, Tewodros W. Shegute, Zong-Shin Lin, Chen-Shiou Wu, Yu-Han Wang, Jennifer K. Litton, Qingqing Ding, Yongkun Wei, Yu-Yi Chu, Funda Meric-Bernstam, Helen Piwnica-Worms, Banu Arun, Jordi Rodon Ahnert, Jinsong Liu, Jun Yao, Wei-Chao Chang, Hung-Ling Wang, Coya Tapia, Constance T. Albarracin, Khandan Keyomarsi, Shao-Chun Wang, Ying-Nai Wang, Gabriel N. Hortobagyi, Chunru Lin, Liuqing Yang, Dihua Yu, Mien-Chie Hung   +31 more
doaj   +1 more source

C5aR1 inhibition reprograms tumor associated macrophages and reverses PARP inhibitor resistance in breast cancer

Nature Communications
Although Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have been approved in multiple diseases, including BRCA1/2 mutant breast cancer, responses are usually transient requiring the deployment of combination therapies for optimal efficacy.
Xi Li, Alfonso Poire, Kang Jin Jeong, Dong Zhang, Tugba Yildiran Ozmen, Gang Chen, Chaoyang Sun, Gordon B. Mills   +7 more
doaj   +1 more source

PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer

Molecular Cancer
Background Poly (ADP-ribose) polymerase inhibitor (PARPi) resistance poses a significant challenge in ovarian carcinoma (OC). While the role of DOT1L in cancer and chemoresistance is acknowledged, its specific role in PARPi resistance remains unclear ...
Chaohua Liu, Jiana Li, Fei Xu, Lihua Chen, Mengdong Ni, Jiangchun Wu, Haiyun Zhao, Yangjun Wu, Jiajia Li, Xiaohua Wu, Xiaojun Chen   +10 more
doaj   +1 more source

Strategic combination of DNA damaging agent and PARP inhibitor results in enhanced cytotoxicity

Frontiers in Oncology, 2013
PARP inhibitors (PARPi) are under clinical trial for combination cancer chemotherapy. In the presence of a PARPi, PARP-1 binds DNA strand breaks but cannot produce poly(ADP-ribose) polymers or undergo auto-poly(ADP-ribosyl)ation.
Julie K. Horton, Samuel H. Wilson
doaj   +1 more source

Prexasertib and Olaparib: overcoming PARPi resistance in high-grade serous ovarian carcinoma

, 2023
BACKGROUND Ovarian cancer is the 1st cause of death due to gynecological cancer and is the 5th cause of cancer death in woman . Since the approval of PARPi the progression free survival and the global survival rates have improved significantly in ...
Ramirez de Cartagena i Fuentes, Mariona
core   +1 more source

DNA topoisomerase IIß inhibition blocks DNA end resection and synergizes with PARPi in BRCA1-deficient models

DNA end resection is a critical step that governs how a broken chromosome will be repaired. As such, it is heavily regulated by multiple cellular signals and processes.
Camarillo Daza, María Rosa, Serra, Violeta, Prados Carvajal, Rosario, Cruz-García, Andrés, Herencia-Ropero, Andrea, Jimeno González, Sonia, Huertas Sánchez, Pablo, Rodríguez Real, Guillermo   +7 more
core   +1 more source

Supplementary Data Figure S1-S4 from PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness

, 2019
PARPi activates DNA damage responses and STING signaling ...
Guang Peng (254279), Timothy A. Yap (11887076), Yang Peng (486260), Jianfeng Shen (1552729), Wei Zhao (14321), Marilyne Labrie (445743), Zhenlin Ju (674024), Gordon B. Mills (6841554), Lulu Wang (804900)   +8 more
core   +1 more source

Emergence of BRCA Reversion Mutations in Prostate Cancer Prior to PARP Inhibitor Exposure: Clinical and Therapeutic Implications

Cancer Medicine
Background Inactivating BRCA1/2 mutations confer sensitivity to poly(ADP‐ribose) polymerase inhibitors (PARPi) in prostate cancer (PCA). However, secondary BRCA1/2 reversion mutations (BRCArev) can restore BRCA function and mediate acquired PARPi ...
Douglas I. Lin, Elizabeth Lawrence, Natalie Danziger, Huihui Ye, Brennan Decker, Ole Gjoerup, Ryon P. Graf, Jeffrey S. Ross, Richard S. P. Huang, Julia A. Elvin, Douglas A. Mata, Rana R. McKay   +11 more
doaj   +1 more source

Epifluorescence imaging of PARPi-FL uptake post irradiation.

, 2016
(A) Representative epifluorescence images of excised FaDu xenografts and mouse tongues. Displayed are fluorescence only, photograph only and composite images.
Wolfgang A. Weber (226149), Thomas Reiner (848165), Susanne Kossatz (848164)   +2 more
core   +1 more source